title: Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease.
abstract: Cardiovascular disease is an important cause of mortality among patients with chronic kidney disease (CKD). This study describes associations between CKD, cardiac revascularization strategies, and mortality among patients with CKD and cardiovascular disease. All patients undergoing cardiac catheterization at Duke University Medical Center (1995 to 2000) with documented stenosis > or =75% of at least one coronary artery and available creatinine data were included. CKD was staged using creatinine clearance (CrCl) derived from the Cockcroft-Gault formula (normal, > or = 90 ml/min; mild, 60 to 89 ml/min; moderate, 30 to 59 ml/min; severe, 15 to 29 ml/min). Cox proportional-hazard regression estimated the relationship between clinical variables, including CrCl and percutaneous coronary artery intervention (PCI), coronary artery bypass grafting (CABG), medical management, and patient survival. There were 4584 patients included, and 24% had CrCl <60 ml/min. Each 10-ml/min decrement in CrCl was associated with an increase in mortality (hazard ratio, 1.14; P < 0.0001). CABG was associated with a survival benefit among patients with both normal renal function and patients with CKD compared with medical management. In patients with normal renal function, CABG was not associated with survival benefit over PCI. However, in patients with CKD, CABG was associated with improved survival. PCI was associated with a survival benefit compared with medical management among patients with normal, mildly, and moderately impaired renal function. Among patients with severe CKD, PCI was not associated with improved survival. CABG is associated with greater mortality reduction than PCI in severe CKD.
authors.affiliation: Duke Institute for Renal Outcomes Research and Health Policy, Division of Nephrology, Duke Clinical Research Institute, Duke University Medical Center, Duke University Medical Center, Durham, North Carolina, USA. dreddan@eircom.net
authors.forename: Donal N
authors.initials: DN
authors.lastname: Reddan
authors.forename: Lynda Anne
authors.initials: LA
authors.lastname: Szczech
authors.forename: Robert H
authors.initials: RH
authors.lastname: Tuttle
authors.forename: Linda K
authors.initials: LK
authors.lastname: Shaw
authors.forename: Robert H
authors.initials: RH
authors.lastname: Jones
authors.forename: Steve J
authors.initials: SJ
authors.lastname: Schwab
authors.forename: Mark Stafford
authors.initials: MS
authors.lastname: Smith
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Mark
authors.forename: William F
authors.initials: WF
authors.lastname: Owen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000401:mortality* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome